Literature DB >> 9635170

End tidal halothane concentration and postoperative analgesia requirements in dogs: a comparison between intravenous oxymorphone and epidural bupivacaine alone and in combination with oxymorphone.

K E Torske1, D H Dyson, G Pettifer.   

Abstract

The purpose of this study was to compare the effects of epidural bupivacaine (BUP) and oxymorphone/bupivacaine (O/B) and intravenous (i.v.) oxymorphone (IVO) on halothane requirements during hind end surgery and postoperative analgesia in 24 dogs. Dogs were randomly assigned to treatment groups: O/B--oxymorphone (0.1 mg/kg) in 0.75% bupivacaine (1 mg/kg for a total volume of 0.2 ml/kg); BUP--0.5% bupivacaine (1 mg/kg for a total volume of 0.2 ml/kg) with i.v. oxymorphone (0.05 mg/kg) postoperatively; and IVO--oxymorphone (0.05 mg/kg) pre- and postoperatively. Heart rate (HR), respiratory rate, arterial blood pressure, end-tidal carbon dioxide and halothane, and arterial blood gases were recorded prior to treatment and every 15 minutes thereafter. Once surgery had begun, end-tidal halothane concentrations were decreased as low as possible while still maintaining a stable anesthetic plane. Data were analyzed using ANOVA with P < 0.05 considered significant. End-tidal halothane requirements did not differ significantly among treatments. Respiratory depression was increased and HR was decreased in the O/B and IVO groups. Postoperative analgesic requirements were significantly less in dogs receiving O/B.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635170      PMCID: PMC1539403     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  22 in total

1.  Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat.

Authors:  J P Penning; T L Yaksh
Journal:  Anesthesiology       Date:  1992-12       Impact factor: 7.892

2.  Problems and precautions when using epidural analgesia for surgery.

Authors:  S C Haskins
Journal:  Vet Clin North Am Small Anim Pract       Date:  1992-03       Impact factor: 2.093

Review 3.  Clinical application of epidural and intrathecal opioids for pain management.

Authors:  N Rawal; U H Sjöstrand
Journal:  Int Anesthesiol Clin       Date:  1986

4.  Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study.

Authors:  N Vesal; P H Cribb; M Frketic
Journal:  Vet Surg       Date:  1996 Jul-Aug       Impact factor: 1.495

5.  Postoperative use of analgesics in dogs and cats by Canadian veterinarians.

Authors:  S E Dohoo; I R Dohoo
Journal:  Can Vet J       Date:  1996-09       Impact factor: 1.008

Review 6.  Somatic pain--pathogenesis and prevention.

Authors:  C J Woolf
Journal:  Br J Anaesth       Date:  1995-08       Impact factor: 9.166

7.  Synergistic antinociceptive interaction after epidural coadministration of morphine and lidocaine in rats.

Authors:  M Kaneko; Y Saito; Y Kirihara; J G Collins; Y Kosaka
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

8.  Specific enhancement by fentanyl of the effects of intrathecal bupivacaine on nociceptive afferent but not on sympathetic efferent pathways in dogs.

Authors:  C Wang; M K Chakrabarti; J G Whitwam
Journal:  Anesthesiology       Date:  1993-10       Impact factor: 7.892

9.  Epidural vs. intramuscular oxymorphone analgesia after thoracotomy in dogs.

Authors:  S Popilskis; D Kohn; J A Sanchez; P Gorman
Journal:  Vet Surg       Date:  1991 Nov-Dec       Impact factor: 1.495

10.  Analgesia after lateral thoracotomy in dogs. Epidural morphine vs. intercostal bupivacaine.

Authors:  P J Pascoe; D H Dyson
Journal:  Vet Surg       Date:  1993 Mar-Apr       Impact factor: 1.495

View more
  1 in total

Review 1.  An Update on Drugs Used for Lumbosacral Epidural Anesthesia and Analgesia in Dogs.

Authors:  Paulo V M Steagall; Bradley T Simon; Francisco J Teixeira Neto; Stelio P L Luna
Journal:  Front Vet Sci       Date:  2017-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.